ECOG-ACRIN EA6174: STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

Objective

This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

https://clinicaltrials.gov/ct2/show/NCT03712605

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Research Studies

Specialties

• Skin Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]